ArticleNature communications2025
NIR-II-excited off-on-off fluorescent nanoprobes for sensitive molecular imaging in vivo.
Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Self-assembled chemiluminescent nanoprobes based on α,α-dicyanoolefins: leveraging a dioxetane "funnel" for high-contrast inflammation imaging.Chemical science · 2026Article
- NIR-II Fluorescent Nanoplatforms with Defect-Regulated Piezoelectricity for Dual NIR-II/MRI-Guided, Hypoxia-Resilient Piezo-Chemodynamic Therapy and cGAS-STING Activation in Orthotopic Liver Tumor.Small (Weinheim an der Bergstrasse, Germany) · 2026Article
- Charge-regulated hepatic γ-glutamyltranspeptidase fluorescent probe:Chemical science · 2026Article
- pH/NIR dual-responsive implantable patch for combined photothermal and chemotherapy of tumors.International journal of pharmaceutics: X · 2026Article
- A renally clearable tumor-targeted probe enabling functional delineation of tumor margins by NIR-II fluorescence lifetime imaging.Materials today. Bio · 2026Article
- Mild-Sunlight-Activated Safe Photodynamic Therapy Using On-Off Polymer Photosensitizers in Wearable Microneedle Patch.Nature communications · 2026Article
- Cysteine imaging reveals early redox dysregulation and identifies gnetol as a ferroptosis-modulating agent in doxorubicin cardiotoxicity.Redox biology · 2026Article
- NIR-II imaging-guided nanoplatform for synergistic mitochondria-targeted pyroptosis and macrophage reprogramming immunotherapy.Materials today. Bio · 2026Article
- Article
- Mitochondria-localized photocatalyst of biomimetic organic semiconductor nanoparticles for NIR-activatable photocatalytic immunotherapy.Science advances · 2025Article
- Light-triggered nanocarriers for nucleic acid delivery.Drug delivery · 2025Review
- Illuminating the Invisible: Fluorescent Probes as Emerging Tools for Micro/Nanoplastic Identification.International journal of molecular sciences · 2025Review
- Near-Infrared-II Fluorescence Imaging of Tumors with Organic Small-Molecule Fluorophores.Sensors (Basel, Switzerland) · 2025Review
- GdACS applied materials & interfaces · 2025Article
- Granzyme B activated near-infrared-II ratiometric fluorescent nanoprobe for early detection of tumor response to immunotherapy.Nature communications · 2025Article
- The construction of TbRSC advances · 2025Article
- A Multi-Threshold Micelle Improves Tumor Accumulation and STING Immunotherapy.Journal of the American Chemical Society · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Strong background interference signals from normal tissues have significantly compromised the sensitive fluorescence imaging of early disease tissues with exogenous probes in vivo, particularly for sensitive fluorescence imaging of early liver disease due to the liver's significant uptake and accumulation of exogenous nanoprobes, coupled with high tissue autofluorescence and deep tissue depth. As a proof-of-concept study, we herein report a near-infrared-II (NIR-II, 1.0-1.7 μm) light-excited "off-on-off" NIR-II fluorescent probe (NDP). It has near-ideal zero initial probe fluorescence but can turn on its NIR-II fluorescence in liver cancer tissues and then turn off the fluorescence again upon migration from cancer to normal tissues to minimize background interference. Due to its low background, a blind study employing our probes could identify female mice with orthotopic liver tumors with 100% accuracy from mixed subjects of healthy and tumor mice, and implemented sensitive locating of early orthotopic liver tumors with sizes as small as 4 mm. Our NIR-II-excited "off-on-off" probe design concept not only provides a promising molecular design guideline for sensitive imaging of early liver cancer but also could be generalized for sensitive imaging of other early disease lesions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.